Catalyst Pharmaceutical (CPRX) saw a 6.7% increase in its share price, closing at $27.68, attributed to notable trading volume in the last session. The stock has gained 9% over the past month. The company’s performance is bolstered by the continued growth of Firdapse, a treatment for Lambert-Eaton myasthenic syndrome, alongside its second drug, Agamree, approved for Duchenne muscular dystrophy, enhancing its revenue streams.
The financial outlook for Catalyst shows expected quarterly earnings of $0.63 per share, which reflects a 7.4% decline year-over-year, while revenues are projected to be $147.08 million, marking a 4% increase from the previous year. In contrast, USANA Health Sciences (USNA) closed at $19.24, down 1.4%, with a consensus EPS estimate of $0.44, indicating a significant 39.7% drop from last year.
